ExAblate Transcranial MR Guided Focused Ultrasound for the Treatment of Essential Tremors
Status: | Active, not recruiting |
---|---|
Healthy: | No |
Age Range: | 22 - Any |
Updated: | 4/17/2018 |
Start Date: | May 2013 |
End Date: | December 2019 |
A Pivotal Study to Evaluate the Effectiveness and Safety of ExAblate Transcranial MRgFUS Thalamotomy Treatment of Medication Refractory Essential Tremor Subjects
The objective of this prospective, randomized, double-blind (to subjects, local site's
blinded assessor and Tremor Core Lab assessors), crossover, multi-site, two-arm study
(ExAblate treated arm Vs ExAblate Sham treated control arm) is to test the efficacy of
treatment using the ExAblate Transcranial System and to further demonstrate safety in
medication-refractory tremor in subjects with essential tremor (ET).
blinded assessor and Tremor Core Lab assessors), crossover, multi-site, two-arm study
(ExAblate treated arm Vs ExAblate Sham treated control arm) is to test the efficacy of
treatment using the ExAblate Transcranial System and to further demonstrate safety in
medication-refractory tremor in subjects with essential tremor (ET).
This study is evaluating a new technique for performing Thalamotomy for tremor control. While
current techniques have possible invasive or radiation effects, the use of ExAblate if
totally non-invasive and without any radiation. After informed consent and screening,
eligible subjects will be randomized to either an ExAblate treatment or an ExAblate Sham or
"fake" procedure. The chance of randomization to Sham is one out of four. Subjects who are
randomized to Sham Control will undergo the same procedure and follow-up visits through their
Month 3 visit. After the Month 3 assessments are complete, all subjects will be unblinded and
those in the Sham treated group will have the option for an actual ExAblate treatment in an
unblinded fashion, as long as they still qualify for ExAblate treatment. All subjects will be
followed at 6 and 12 months and for up to 5 years as directed by their doctor.
current techniques have possible invasive or radiation effects, the use of ExAblate if
totally non-invasive and without any radiation. After informed consent and screening,
eligible subjects will be randomized to either an ExAblate treatment or an ExAblate Sham or
"fake" procedure. The chance of randomization to Sham is one out of four. Subjects who are
randomized to Sham Control will undergo the same procedure and follow-up visits through their
Month 3 visit. After the Month 3 assessments are complete, all subjects will be unblinded and
those in the Sham treated group will have the option for an actual ExAblate treatment in an
unblinded fashion, as long as they still qualify for ExAblate treatment. All subjects will be
followed at 6 and 12 months and for up to 5 years as directed by their doctor.
Inclusion Criteria:
- Men and women, age 22 years and older
- Subjects who are able and willing to give informed consent and able to attend all
study visits
- Subjects with a diagnosis of Essential Tremor as confirmed from clinical history and
examination by a neurologist or neurosurgeon specialized in movement disorder
- Subject exhibits a significant disability from their ET despite medical treatment
- Subjects should be on a stable dose of all ET medications for 30 days prior to study
entry
- Subject is able to communicate sensations during the ExAblate Transcranial procedure
Exclusion Criteria:
- Subjects with unstable cardiac status
- Severe hypertension
- Subjects with standard contraindications for MR imaging such as non-MRI compatible
implanted metallic devices including cardiac pacemakers, size limitations, etc.
- Known intolerance or allergies to the MRI contrast agent including advanced kidney
disease or severely impaired renal function
- Significant claustrophobia that cannot be managed with mild medication
- Current medical condition resulting in abnormal bleeding and/or coagulopathy
- Receiving anticoagulant (e.g. warfarin) or antiplatelet (e.g. aspirin) therapy within
one week of focused ultrasound procedure or drugs known to increase risk or hemorrhage
- History of intracranial hemorrhage
- History of multiple strokes, or a stroke within past 6 months
- Subjects who are not able or willing to tolerate the required prolonged stationary
supine position during treatment
- Are participating or have participated in another clinical trial in the last 30 days
- Subjects unable to communicate with the investigator and staff
- Subjects with a history of seizures within the past year
- Subjects with brain tumors
We found this trial at
6
sites
Stanford Univ Med Ctr The Medical Center is uniquely advantaged by its location on the...
Click here to add this to my saved trials
Brigham and Women's Hosp Boston’s Brigham and Women’s Hospital (BWH) is an international leader in...
Click here to add this to my saved trials
Click here to add this to my saved trials
University of Virginia The University of Virginia is distinctive among institutions of higher education. Founded...
Click here to add this to my saved trials
Swedish Medical Center Since 1910, Swedish has been the region's hallmark for excellence in health...
Click here to add this to my saved trials
Click here to add this to my saved trials